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BIOMARKER: DEFINITION  
AND CHARACTERISTICS
To predict cardiovascular and neurodegenerative risk, 
numerous biomarkers have been developed. Some of 
them are simple traditional biomarkers based on lipid 
profile and risk factors. Biomarkers are used in medi-
cine to facilitate diagnosis, assess risk, direct therapy 
and determine efficacy of treatment. 
In the World Health Organization definition a bio-
marker is any substance, structure, or process that can 
be measured in the body. A clinically useful biomarker 
must be able to meet one of the following criteria: i) 
show specificity and sensitivity for a certain disease (di-
agnostic); ii) have prognostic value; and iii) correlate 
with disease activity. A biomarker may be measured on 
a biosample (as blood, urine, or tissue test), it may be 
a recording obtained from a person (blood pressure, 
ECG, or Holter), or it may be an imaging test (echo-
cardiogram or CT scan).
SEX-RELATED BIOMARKERS  
IN CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is the number one 
cause of death in industrialized countries. To estimate 
CVD risk, the Framingham Risk Score lists eight bio-
markers considered classical risk factors [1]. Moreover, 
an increasing number of novel biomarkers, particularly 
markers of both inflammation and atherosclerotic bur-
den, have been added to the classical risk factors. The 
classical risk factors include, some such as hyperten-
sion, diabetes, abnormal cholesterol, smoking, physical 
inactivity, and obesity that are considered modifiable; 
others, such as age, family history, and sex that are 
considered non modifiable. Novel biomarkers include 
molecules circulating in the blood or urine that can be 
used for both the diagnosis and the prevention of CVD. 
These molecules can be classified on the basis of their 
function (e.g., marker of exposition, markers of effects, 
etc.) or in their biochemical or biologic properties (e.g., 
proteins metabolites, hormones, cytokines, etc.). 
Several epidemiological studies, in particular the 
Framingham [1], have investigated into the evolution 
of CVD hypothesizing the presence of a sex difference 
in the pathogenetic and progression determinants de-
tectable in women and men.
Women and men differ in their manifestations of 
CVD in a multitude of ways. For instance, women de-
velop CVD when they are about 10 years older than 
men and typically after the menopause [2]. Marked sex 
differences have been identified in the clinical manifes-
tations of atherosclerosis and in the pattern of symp-
toms in the two sexes. In men, cholesterol has a main 
role than in women, in whom arterial hypertension, dia-
betes, and their combination has a greater importance 
in determining cardiovascular risk.
In women, the control of blood pressure and glucose 
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Abstract
Despite considerable advances in the treatment of human inflammatory diseases, such 
as cardiovascular and neurological disorders, they remain the leading cause of death in 
developed countries. From a clinical perspective, an active area of investigation focuses 
on the identification of diagnostic and prognostic biomarkers, because preventing events 
in those at risk of chronic inflammatory disease is likely to have a substantial impact on 
the overall public-health burden. The sex difference has not been considered previously as 
important in the evaluation of biomarkers of human diseases, notwithstanding it is now 
ascertained that the severity of these disorders is correlated with sex hormones which 
modulate the inflammatory response. The aim of the present brief review is to report and 
comment the state of art regarding the sex-related biomarkers in cardiovascular and neu-
rodegenerative disorders, focusing on those compounds showing potential prognostic- 
and diagnostic values, and/or acting as indicators of the therapeutic treatment efficacy.
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metabolism should be a priority. Angina, the most com-
mon manifestation of coronary heart disease (CHD), 
is frequently uncomplicated in women, whereas in men 
it tends to evolve to an acute coronary syndrome. The 
clinical presentation of acute ischemic syndromes is 
also different in men and women and, because of the 
frequent atypical symptoms, women tend to underes-
timate the importance of them. However, considering 
that women are often excluded from research studies, 
sex differences in CVD remain a frontier for discovery. 
In this review only novel biomarkers sex-associated will 
be reported (Table 1).
Among novel biomarkers considered inflammatory 
markers, C-reactive protein (CRP), soluble CD40 li-
gand (sCD40L), IL-18, monocyte chemotactic pro-
tein-1 (MCP-1), and fibrinogen, have been typically 
linked to endothelial cell (EC) activation. In human 
plasma, CRP levels are one of the most powerful pre-
dictors of atherosclerosis and vascular death, and have 
been associated with risk of acute myocardial infarc-
tion, angina, and stroke. Higher CRP levels in women 
than in men have been reported [3, 4]. sCD40L, re-
leased in the peripheral blood from ECs, macrophages, 
activated T lymphocytes, and platelets, is involved in 
the pathogenesis of atherosclerosis via its inflammatory 
and prothrombotic properties. An association between 
high levels of sCD40L and CRP with microalbuminuria 
has been found in hypertensive premenopausal women 
and not in men [5].
IL-18, a member of the IL-1 cytokine family, is 
highly expressed in atherosclerotic plaques. After post-
myocardial infarction its concentration has been found 
higher in men [6]. MCP-1 is a chemokine responsible 
for the recruitment of monocytes to sites of inflamma-
tion that appears to play a critical role in the promotion 
of plaque instability [7]. Different levels of MCP-1 have 
been found between men and women. In particular, it 
has been shown that the subjects with high estrogen 
status have significantly lower plasma MCP-1 levels 
than subjects with low estrogen status [8].
Fibrinogen is a glycoprotein mainly synthesized in 
hepatic cells and in megakaryocytes. It can bind to 
GpIIB/IIIa surface proteins creating bridges between 
platelets. Moreover, being involved in the coagulation 
cascade, fibrinogen stimulates smooth muscle cell mi-
gration, promotes platelet aggregation, and increases 
blood viscosity [9]. Fibrinogen is associated with ath-
erosclerosis and thrombosis and is considered an in-
dependent risk factor for CHD, myocardial infarction 
(MI), and stroke. It has been reported that fibrinogen 
levels are generally higher in women than in men of the 
same age, and that in women plasma fibrinogen rises 
with menopause [10].
It is known that endothelial dysfunction is a risk fac-
tor for ischemic events such as stroke, myocardial in-
farction, unstable angina pectoris, ventricle fibrillation, 
and death from cardiovascular reasons. It has been hy-
pothesized that some soluble molecules play an impor-
tant role in the pathogenesis of EC injury and progres-
sive formation of atherosclerotic lesions. Among these 
molecules, soluble intercellular adhesion molecule-1 
(sICAM-1), soluble P-selectin (sP-selectin), asymmet-
ric dimethylarginine (ADMA), and oxidized low-densi-
ty lipoprotein (ox-LDL) are sex-associated biomarkers. 
sICAM-1 and sP-selectin have been demonstrated to 
promote the adherence of monocytes and lymphocytes 
to ECs contributing to atheroma formation [11].
sICAM-1 has been associated with increased risk of 
CVD-associated death in women but not in men [12].
sP-selectin mediates the rolling of blood cells on the 
surface of the endothelium and initiates the attach-
ment of leukocytes circulating in the blood to platelets, 
ECs, and other leukocytes at sites of tissue injury and 
inflammation. Its levels have been found higher in the 
hypertensive patients, and significantly higher in the hy-
pertensive patients with diabetes [13]. In relation to sex 
disparity, higher levels of sP-selectin have been detected 
in plasma from men with metabolic syndrome [14].
ADMA is an endogenous competitive nitric oxide 
synthase (NOS) inhibitor derived from the hydrolysis 
of methylated proteins and is constantly produced in 
the course of normal protein turnover in many tissues, 
including vascular ECs. An increase of ADMA plasma 
levels induces endothelium dysfunction, which be-
comes clinically evident by impaired endothelium-de-
pendent vasodilation, platelets hyperaggregability, and 
enhanced monocyte adhesion [15, 16]. Interestingly, 
sex- and age-dependent differences have been found in 
ADMA plasmatic concentration (i.e. increased in plas-
ma of women at the onset of menopause with respect to 
age-matched men) [17]. 
Ox-LDL may be formed by oxidative processes dur-
ing migration of the LDL particles in the vessel wall. 
Its plasma levels are correlated with the presence of 
thrombotic lesion morphology in patients with unstable 
angina. Ox-LDL binds to a lectin-like specific recep-
tor, a membrane glycoprotein expressed in ECs, mac-
rophages, VSM cells, and platelets, and induces ath-
erosclerosis by stimulating monocyte infiltration and 
smooth muscle cell migration and proliferation. Its plas-
ma levels are correlated with the presence of thrombot-
ic lesion morphology in patients with unstable angina. 
Increasing levels of ox-LDL seem to be preferentially 
associated with loss of systolic function in men (with 
less impairment of diastolic function). By contrast, in 
women, systolic function remains better preserved but 
with decreasing diastolic function.
Brain natriuretic peptide (BNP), a member of the 
natriuretic peptide family, is a biomarker reflecting left 
Table 1
Sex-associated biomarkers in cardiovascular diseases
Men Women
IL-18 CRP
MCP-1 sCD40
sP-selectin Fibrinogen
ox-LDL s-ICAM
ADMA
BNP
Troponin
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ventricular dysfunction. In healthy populations, women 
tend to have higher levels of BNP than do men, perhaps 
as a result of estrogen-mediated stimulation and andro-
gen-mediated suppression. This sex-specific difference 
seems to be less pronounced in the settings of heart 
failure and other disease states in which natriuretic pep-
tides are upregulated. 
Troponin is a component of the contractile apparatus 
in the myocardium. Its circulating levels are essential 
for diagnostic assessment and risk prediction in patients 
with symptoms of unstable coronary artery disease.
In both sexes, higher levels of troponin predict an in-
creased risk of death or MI, although troponin seems 
to be a stronger marker of recurrent MI in women than 
in men.
SEX-RELATED BIOMARKERS IN 
NEURODEGENERATIVE DISEASES 
The mammalian brain is sexually dimorphic, exhib-
iting significant structural and functional differences 
between the sexes [18] as well as different vulnerabil-
ities to Central Nervous System (CNS) disorders in-
cluding some neurodegenerative diseases (ND), such 
as Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) [18]. Accurate diagnosis of ND will be crucial to 
treatment development and ultimately, to the ability to 
offer earlier effective therapeutic interventions. Defini-
tive diagnosis in non-genetic ND can currently be made 
with histopathological confirmation, and usually only at 
post-mortem examination [19]. In vivo clinical diagno-
sis of ND is difficult especially in the earliest stages: 
specialist centers typically only achieve an accurate pre-
mortem diagnosis in 70-90% of cases [19]. Tremendous 
efforts have been made in recent years to identify the 
neuropathological, biochemical, and genetic biomark-
ers of the diseases so that the diagnosis could be estab-
lished in the earlier stages [20]. At the time, some blood, 
plasma, serum or cerebrospinal fluid (CSF) biomarkers 
for detection and tracking of the preclinical and clini-
cal stages of AD have been proposed. These methods 
include CSF detecting levels of amyloid-β (Aβ42), total 
tau (t-tau) and phospho-tau (p-tau) [21], for AD, while 
probably alpha-synuclein is the most promising assay 
for diagnosis and evolution of PD [22]. Furthermore, 
neuroimaging techniques may provide useful adjunc-
tive information for the early diagnosis of neurodegen-
erative disorders: magnetic resonance imaging (MRI), 
functional MRI and positron emission tomography 
(PET) scan imaging, as well as neuropsychological tests 
for cognitive performance. However, there is a press-
ing need for efficient, cost-effective biomarkers that can 
help to diagnose patients earlier and more accurately to 
improve the therapeutic prospects.
Sex differences in vulnerability to neurological disor-
ders might be due to sexual dimorphisms established 
during development as well as to adult brain levels of 
the steroid hormones 17β-estradiol (E2), progesterone, 
testosterone and their metabolites. Research has been 
extensive in trying to understand the interactions of sex 
chromosomes and hormones and the underlying mech-
anisms of these devastating disorders [23].
The 2015 World Alzheimer Report updates data on 
the prevalence, incidence, cost and trends of dementia 
worldwide. With reference to Italy (the country with the 
largest number of studies), approximately 1.2 million of 
Italians are affected by Dementias [25]. 
AD is a chronic degenerative disease characterized 
by extracellular amyloid plaques resulting from the ac-
cumulation of Aβ42 and intracellular neurofibrillary 
tangles due to the aggregation of tau proteins [25]. 
Diagnosis of AD is based on subjective neuropsycho-
logical tests supplemented by late-stage biomarkers in 
CSF [26]. The early diagnosis may be important be-
fore the irreversible brain damage or mental decline 
has occurred. AD is more prevalent in women than in 
men. Although the incidence of AD in men and women 
increases robustly with age [27, 28], these age-related 
changes are not known, but many studies revealed that 
there has been surprisingly little research into the ef-
fect of sex on dementia. For instance, women getting 
AD also demonstrate greater cognitive declines com-
pared with men. This even includes verbal skills that 
are stronger in healthy females compared with males 
[29-31]. These conditions suggest that there may be 
important sex differences among the possible biomark-
ers for AD, more specific in women or in men and that 
their discovery is important not only for the diagnosis, 
but also when studying the pathways involved in AD 
pathology. An Italian study comparing the results of 
18FDG-PET imaging in men and women with equally 
severe AD showed that women had significantly higher 
glucose metabolism in the areas primarily involved in 
the pathological process of AD (the right inferior fron-
tal, superior temporal and insular cortices, and the hip-
pocampus), suggesting a sex difference in the disease 
process [32, 33].
Sex differences in the brain, such as in brain anato-
my, age-related declines in brain volume, and brain glu-
cose metabolism, have been documented and may be 
important in understanding AD etiology. Some genes 
involved in Familial Alzheimer’s Disease (FAD) as pre-
senilin 1 (PSEN1) and presenilin 2 (PSEN2) are widely 
expressed during brain development. Several mutations 
in these proteins have been associated with autosomal-
dominant inherited forms of AD [34-40]. Their expres-
sion is regulated by various cellular and extracellular 
factors, which change with age and sex. Both age and 
sex are key risk factors for AD, but the issue of whether 
the expression of presenilins (PSENs) was influenced 
by the sex during brain development had been poorly 
investigated. Our study showed that both the transcript 
levels of PSENs, and the subset of neurons expressing 
these proteins in various brain areas of the developing 
post-natal brain have a different distribution in male 
and female rats, suggesting that their function(s) may 
contribute to sexual dimorphism in the brain, both at 
morphological and functional levels [41]. 
However, the full impact of sex as a basic biologic 
variable on this pathology remains elusive [42]. AD 
pathogenesis in women may be influenced by meta-
bolic changes induced by gonadal hormones, such as 
estrogen, which is known to have a protective effect on 
the brain. Loss of estrogen during menopause could, 
in part, lead to the deficits seen in brain metabolism in 
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Mild Cognitive Impairment (MCI) and AD. Transgenic 
animal studies have provided evidence that both male 
and female gonadal hormones regulate AD pathogen-
esis. [43-45]. Current diagnosis methods are helpful in 
detecting ND when CNS damage has already occurred. 
The use of effective biomarkers has great significance 
for the prediction, diagnosis, monitoring, treatment, 
and prognosis of many diseases. Should be important 
to detect AD at very early stages to improve the thera-
peutic prospects. 
In the last few years, some sex specific biomarkers 
for the identification of AD have been described (Table 
2). Koran and colleagues found a significant interac-
tion between sex and Aβ42 and total tau on longitu-
dinal hippocampal atrophy and longitudinal decline in 
memory and executive function. They described that 
women with Aβ42 and total tau levels indicative of 
worse pathological changes, showed more rapid hippo-
campal atrophy and cognitive decline (46). Moreover, 
Ribeiro and colleagues showed that transthyretin (TTR) 
decreased in the CSF of AD patients suggesting that 
TTR could be a potential CSF biomarker in AD. In 
details, in MCI and AD groups, women showed sig-
nificantly lower plasma TTR levels when compared to 
MCI and AD men, respectively, and to women control 
group. In the AD women group, TTR levels correlated 
with disease stage, reflecting disease severity. Moreover, 
the plasma estradiol levels in women and men showed 
a reduction in both groups. Thus, this study prompts 
TTR as an early plasma biomarker in AD indicating that 
disease modulation by TTR is sex dependent [47].
Another protein of interest, the progranulin (PGRN), 
constitutes a potentially invaluable biomarker for ND 
including frontotemporal lobar degeneration (FTLD) 
and AD. In fact, our study trying to assess the plasma 
PGRN levels in 107 AD patients, 36 FTLD patients, 
and 107 controls, showed that in female AD patients 
there was a positive correlation between PGRN levels 
and age. Although no significant differences were found 
between patients and controls, we showed higher lev-
els of PGRN in females compared to males; in AD pa-
tients, a positive correlation between PGRN levels and 
age was observed in females, suggesting a sex-related 
involvement of PGRN in the pathogenesis of AD [48].
The Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) program hypothesized that plasma leptin, a 16 
kDa peptide hormone synthesized and secreted specifi-
cally from white adipose cells, in individuals with MCI 
or AD could be a good biomarker. In fact, its levels were 
found lower than those of subjects with normal cogni-
tion (NC). Approximately 70% of both men and wom-
en with MCI have plasma leptin levels lower than the 
median values of NC. Additionally, half of these sub-
jects carry at least one apolipoprotein-E4 (APOE-ε4) 
allele. A subgroup of participants also had CSF leptin 
measured. Plasma leptin typically reflected the levels of 
the peptide in CSF in all groups (Control/MCI/AD) 
in both sex. The data suggest that plasma leptin defi-
ciency provides an indication of potential CNS leptin 
deficiency, further supporting the exploration of plasma 
leptin as a diagnostic marker for MCI or AD. The im-
portant question is whether leptin deficiency plays a 
role in the causation of AD and/or its progression. If 
this is the case, individuals with early AD or MCI with 
low plasma leptin may benefit from leptin replacement 
therapy. Thus, these data indicate that trials of leptin in 
low leptin MCI/early-stage AD patients should be con-
ducted to test the hypothesis. However, when analyzed 
by sex, plasma leptin values in men were approximately 
half those of women regardless of group (NC, MCI or 
AD). MCI men had significantly lower plasma leptin 
than NC men [49].
Also in PD, in which a higher incidence and preva-
lence in men is observed, there are some sex differences. 
In fact, PD occurs more often in men than in women, 
such as described in an interesting meta-analysis per-
formed on seven studies and reporting an increased 
relative risk of 1.5 [50]. Sexual dimorphisms in non-
diseased basal ganglia and substantia nigra may partly 
explain this sex-specific risk. Estrogen, neuroprotective 
to the dopaminergic system may account for some of 
these differences. In addition, chromosome differenc-
es may contribute to the sex differences noted in PD, 
with interplay between chromosomal factors and go-
nadal hormone factors [51]. As well known, the histo-
pathological hallmark of PD is the presence of fibrillar 
aggregates called Lewy bodies in the substantia nigra. 
The observation that α-synuclein is the main protein 
component of these aggregates and the discovery that 
mutations in the α-synuclein (SNCA) gene can cause 
PD suggest a central role for α-synuclein in the disease 
process. Hence, α-synuclein in human body fluids was 
hypothesized as being a good disease-linked candidate 
biomarker for PD [52]. The progressive accumulation 
and spread of α-synuclein pathology in patients with PD 
led to the hypothesis that CSF α-synuclein could par-
ticularly serve as a marker of progression. In fact, CSF 
α-synuclein levels have been shown to correlate inversely 
with PD severity. In our observational cross-sectional 
study performed on 69 patients with AD and 110 con-
trols, we observed a significant sex difference in plasma 
α -synuclein concentrations [53]. In men, α-synuclein 
concentrations differed significantly according to dis-
ease progression. An explanation of these results could 
be related to the fact that the intracellular α-synuclein 
aggregation differs in men and women owing to a pro-
tective hormonal effect in women; in fact, estrogens 
Table 2
Sex-associated biomarkers in neurodegenerative diseases
Disease Men Women
Alzheimer Leptin Amyloid-β42
Total tau
Transthyretin
Progranulin
Parkinson Alpha-synuclein LRRK2
Urate
DJ-1
Amyotrophic lateral 
sclerosis
MTHFR
Testosteron
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dose-dependently inhibit α-synuclein aggregation and 
in particular, estriol and estradiol destabilize preformed 
fibrillar α-synuclein in vitro. Moreover, some in vitro evi-
dences suggest that sex hormones may alter α-synuclein 
expression in the brain. Studying the sex-associated 
genetic expression in dopaminergic neurons, Cantuti-
Castelvetri and colleagues observed a female-associated 
gene up-regulation in signal transduction and neuronal 
maturation [54]. They also observed a men-associated 
up-regulation of genes directly involved in PD patho-
genesis, including α-synuclein: men therefore seem to 
produce more central nervous system α-synuclein than 
women. Caranci and colleagues also described an asso-
ciation between plasma α-synuclein concentrations and 
cognitive impairment, hallucinations, psychosis, apathy, 
sleep disturbances in men but not in women [52]. In-
deed, some studies have highlighted gender-related cog-
nitive dysfunction, such as prevalent deficits in verbal 
fluency and facial expression recognition in males, and 
visual-spatial deficits in women [55]; furthermore, the 
association with sleep disturbances only in male patients 
could reflect the male prevalence in these disorders so 
that several studies have shown an correlation between 
REM sleep behavior disorders and male PD patients. 
Another molecule that could influence the clinical 
progression of PD is urate, a natural oxidant and iron 
chelator. Several studies have found lower plasma urate 
levels in women than in men. The impact of sex on the 
association between urate and PD is controversial. In 
fact, plasma urate in men is described to have an in-
verse correlation with the risk of PD in two prospective 
cohorts, but no sex-specific results were presented in 
another study by De Lau et al [56]; then, more studies 
are needed in the future to define the real influence of 
sex on the association between urate and PD [57]. 
Among biomarkers having sex-differences in PD, 
DJ-1 was found increased in urine exosome of male 
with PD. DJ-1 is an antioxidant protein that is autoxi-
dized when exposed to oxidative stress, protects cel-
lular contents, and regulates the gene expression of 
defense. Because oxidative stress is suspected as one 
of major causes of PD, DJ-1 and oxidized DJ-1 were ex-
tensively studied for their potentials as PD biomarkers 
using various biofluids such as CSF, blood, and saliva. 
Moreover, levels lower in female for leucine-rich repeat 
kinase 2 (LRRK2), another protein associated to PD 
were also found [58]. Mutations in the (LRRK2) gene 
are the most common genetic determinant of Parkinson 
disease (PD) identified to date. Orr-Urtreger and col-
leagues described a mutation of LRRK2 gene (G2019S) 
over-represented in women of Ashkenazi Jews with Par-
kinson disease, suggesting a gender effect on genetic 
frequencies of this mutation [59].
Amyotrophic lateral sclerosis (ALS), so called Lou 
Gehrig’s disease, is a rapidly progressive, invariably fatal 
neurological disease that involves the death of neurons 
responsible for controlling voluntary muscles. The dis-
ease belongs to a group of disorders known as motor 
neuron diseases, which are characterized by the gradual 
degeneration and death of motor neurons.
In ALS most studies have found that sex has no ef-
fect on the disease outcome, but a higher frequency of 
bulbar onset disease was found among older women 
[60]. The search of biomarkers useful for monitoring 
disease progression and assessing treatment effective-
ness is particularly imperative in ALS. Changes in cir-
culating steroids throughout the course of ALS might 
influence the neuroprotective response against neuro-
degenerative damage. Gargiulo-Monachelli and col-
leagues showed that steroids in ALS bear a different 
profile in relation to gender: postmenopausal female 
patients showed significantly higher total (TT) and free 
testosterone (FT) serum levels compared to controls, as 
well as a reduction of progesterone/FT and dehydroepi-
androsterone sulfate (DHEAS)/cortisol ratios [61]. Fa-
milial and sporadic ALS (SALS) have also influenced by 
genetics and some polymorphisms associated to the pa-
thology have been found to be gender-specific. A study 
on methylenetetrahydrofolate reductase (MTHFR) 
gene polymorphisms showed an association between 
female SALS and MTHFR T677T [62].
SEX-RELATED BIOMARKERS OF OXIDATIVE 
STRESS IN CVD AND ND
Reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) participate in the normal aging process 
as well as in age-related diseases, such as atherosclero-
sis and ND. ROS/RNS can cause direct damage to the 
vascular wall, triggering several redox-sensitive signal-
ing pathways, which ultimately cause pro-atherogenic 
changes. In clinical practice, the analytical measure-
ment of ROS/RNS is very difficult due to their short 
half-life and to the applicability of the determination 
methods. The localization and effects of oxidative 
stress, as well as information regarding the nature of the 
ROS/RNS, may be gleaned from the analysis of discrete 
biomarkers of oxidative stress damage isolated from tis-
sues and biological fluids.
Clinical studies have demonstrated a relationship 
between oxidative stress and inflammatory biomark-
ers. Inflammation plays a major role in life, allowing 
the organism to restore homeostatic balance in the case 
of infection and traumatic or ischemic tissue damage. 
Human inflammatory disorders, such as CVD and ND, 
are subjected to redox control being strongly modulated 
by the levels of ROS/RNS [63-66]. In inflamed tissues, 
ROS/RNS formation is increased by the activation of 
the related ROS/RNS-producing enzymes, and trig-
ger diseases: i) by reaching concentrations that exceed 
cellular antioxidant defense mechanisms, ii) being pro-
duced in inappropriate cellular compartments, or iii) 
through a shift in the type of ROS/RNS being formed. 
Under these conditions, better known as oxidative 
stress, all the major cellular components (proteins, lip-
ids, carbohydrates, nucleic acids, antioxidants) undergo 
oxidation and typical reversible/irreversible post-tran-
scriptional modification reactions occur (i.e., oxidation, 
nitrosation, nitration). Consequently, cell undergoes to 
death not only for the increase of irreversible oxidative 
damage, but also for the antioxidant inability to reduce 
the reversible modifications, which accumulate. In view 
of these events, clinical relevance of oxidative stress 
biomarkers has been critically analyzed for their ability 
to be used in both healthy and pathological conditions, 
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with prognostic- and diagnostic values, as well as indi-
cators of the therapeutic treatment efficacy [64-66].
Convincing evidence for the association of oxidative/
nitrosative/nitrative stress and acute/chronic diseases 
lies on validated oxidative stress biomarkers. In gen-
eral, several markers of oxidative stress still represent a 
possible biomarker opportunity for clinical use [64-66]. 
However, visualization of biomarkers measured in hu-
man CVD and ND shows that the majority oxidative 
stress-related target modification is a nuanced phenom-
enon, and their specificity with regards to a single dis-
ease is lost [64, 65]. This phenomenon is conceivable 
bearing in mind that increased ROS/RNS formation 
and redox unbalance are the major causes of inflamma-
tory pathological conditions, so that the same oxidative 
stress-related biomarkers could result altered in differ-
ent inflammatory diseases.
The evaluation of oxidative stress biomarkers in hu-
man healthy and diseased population is particularly 
important when considering that the severity of inflam-
matory status appear to be correlated with the levels 
of female sex hormones [67, 68]. In a healthy popu-
lation, however, it is not clear whether tissue oxidant 
status and redox balance are significantly different be-
tween males and females. Indeed, conflicting results 
have been reported regarding the physiological levels of 
oxidant concentration (superoxide anion- and nitric ox-
ide-derived species), oxidation markers (isoprostanes, 
malondialdehyde, lipid peroxidation), and antioxidant 
levels (glutathione, superoxide dismutase, catalase, glu-
tathione peroxidase, etc.) measured ex vivo in blood of 
males and females [69-71].
Nevertheless, it is now evident that male and female 
hormones differently affect ROS/RNS-driven intracel-
lular activities, thus contributing to explain the gap of 
knowledge between diagnosis, prognosis, and outcome 
of diseases characterized by significant alterations of 
redox state [72]. Indeed, estrogens modulated several 
ROS/RNS-producing enzymes (i.e., NOS, xanthine oxi-
dase, NADPH oxidases, cytochromes, the pro-oxidant 
myeloperoxidase) [72], as well as important antioxidant 
redox-related enzymes [73, 74], among which glutathi-
one peroxidase, whose prognostic value has been re-
cently investigated [73] (Figure 1). This hypothesis was 
Figure 1
Estrogens (E) signaling is thought to affect the activities of ROS/RNS-producing enzymes (pink circles) and redox-related antio-
xidant enzymes (green rectangles) in human tissues by binding to E receptors (ER). In the genomic pathway, E bind to cytosolic/
nuclear ER increasing the transcription of nitric oxide synthase (NOS) leading to increased nitric oxide (·NO) production. In the 
non-genomic pathway, E bind to mitochondrial- and/or membrane-ER. In the first case, the activation of monoamine oxidase 
(MAO) could increase H2O2 production contributing to mitochondrial disfunction. In the second case, the E binding to membrane-
associated ER could i) stimulate Ca2+ release from the endoplasmic reticulum leading to NOS activation, ii) activate Cycloxygena-
ses (COX), Xanthine Oxidase (XO), Cytochrome P450 (Cyt P450) and Myeloperoxidase (MPO), leading to subsequent superoxide 
anion (O2·) and hydrogen peroxide (H2O2) production, strarting chemical cascades generating additional damaging molecules, 
such as ·OH (generated by the O2·/H2O2 reaction with transition metals), peroxynitrite (ONOO-) (generated by the O2· reaction with 
·NO), peroxynitrite-derived highly oxidants, i.e. the carbonate radical (·CO3) and the nitrating agent nitrogen dioxide (·NO2), and 
peroxidase ferryl species; iii) inhibit the activity of the O2·-producing enzyme NADPH oxidases (NOX), iv) increase the activity of 
key antioxidant enzymes, i.e. Superoxide Dismutase (SOD), Glutathione Peroxidase (GPx), glutaredoxin (Grx), and Thioredoxin 
Reductase (TrxR), and v) decrease the concentration of asymmetric dimethylarginine (ADMA), the NOS endogenous inhibitor 
NOS. Dashed lines indicate uncleared mechanisms. Marked in grey: inhibitory effects of E treatments. NO2- and NO3-: nitrite and 
nitrate, respectively.
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supported by the in vivo finding that menopause is as-
sociated with significant down regulation of antioxidant 
gene expression [75]. A possible protective estrogen ef-
fect on vasculature in vivo has been hypothesized, since 
in cell cultures estradiol increased nitric oxide release 
and decreased the concentration of ADMA [76]. Final-
ly, potential understimated oxidative stress biomarkers 
of importance for human inflammatory diseases could 
be the two isoforms of monoamine oxidase (MAO). 
These mitochondrial enzymes generate significant 
hydrogen peroxide amounts in the catalytic process 
leading to the oxidative deamination of endogenous/
exogenous amines, including neurotransmitters. Their 
activity has been reported to be increased in CVD and 
ND and their inhibition allowed beneficial effects in 
animal experimental models of these diseases [64, 66]. 
Interestingly, estrogens have been reported to modu-
late MAO activities (Figure 1), which were decreased in 
amenorrheic and post-menopausal woman after estro-
gen treatment [77]. It is very difficult to draw general 
conclusions on the significance of sex-related oxidative 
stress biomarkers in pathological conditions, because 
even the sex-unrelated oxidative stress biomarkers cur-
rently under study in human diseases still need to be 
validated in larger sample sizes and/or compared with 
current clinical standards to establish them as clini-
cal diagnostics. However, we would underline that the 
growing interest for the redox medicine in human 
health has recently allowed to consider the disease-trig-
gering ROS/RNS-generating enzymes as suitable clini-
cal therapeutic targets for the disease-relevant oxidative 
stress [64, 66]. In the light of the reported evidences, 
a sex-perspective should drive future clinical studies 
before starting any pharmacological modulation and 
drug candidate development regarding oxidative stress-
related human diseases.
CONCLUSIONS
In conclusion, research studies that have looked for 
differences in CDV and ND prevalence, progression, 
and phenotype support differences between men and 
women. However, sex has not been considered previ-
ously important in diagnostic approaches, but should 
be considered in both future clinical and laboratory 
studies. Very little research has been conducted to po-
tentially explain such sex differences in these patholo-
gies. Certainly, no studies of biomarkers have consid-
ered sex, and yet it is entirely possible that development 
of effective treatments may differ by gender. 
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